Aminosalicylates Crohn’s Disease: Why They Fail Most Patients

Aminosalicylates represent a declining therapeutic option for Crohn’s disease, with 2026 data revealing that 78% of IBD specialists now question their clinical value. While these 5-ASA medications continue to appear in treatment protocols, mounting evidence demonstrates their limited efficacy in achieving remission for most Crohn’s patients. Understanding why aminosalicylates underperform and what alternatives deliver measurable results can transform your path from chronic inflammation to sustained wellness. This analysis examines the clinical reality behind aminosalicylate prescriptions and identifies evidence-based approaches that address the root causes of intestinal inflammation.

Quick Answer: Do Aminosalicylates Actually Work for Crohn’s Disease?

The short answer: rarely well enough to matter. Aminosalicylates Crohn’s disease prescriptions have dropped significantly as specialists recognize their limitations compared to other interventions.

• Most gastroenterologists now reserve 5-ASA medications for mild ulcerative colitis, not Crohn’s
• Crohn’s disease involves patchy inflammation that aminosalicylates cannot effectively reach
• Clinical remission rates for Crohn’s patients on aminosalicylates remain below 30%
• Small bowel disease particularly resists topical 5-ASA delivery mechanisms
• 2026 treatment algorithms prioritize immunomodulators and biologics over mesalamine

According to recent findings from Frontiersin, a 2026 nationwide survey of 615 inflammatory bowel disease physicians revealed declining confidence in aminosalicylate therapy for Crohn’s patients. The data confirms what many patients already suspect: the medication they’re prescribed often fails to deliver meaningful relief.

@keyframes hoox-lf-in-hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-top .hoox-disabled-text a:hover {
text-decoration: none;
}

The Clinical Reality: Why 5-ASA Medications Underperform in Crohn’s

The fundamental problem with aminosalicylates in Crohn’s disease comes down to biology and physics. These medications work topically they coat the intestinal lining and deliver anti-inflammatory compounds directly to the mucosal surface. That approach works beautifully for ulcerative colitis, where inflammation stays superficial and continuous throughout the colon.

Crohn’s disease behaves differently. The inflammation penetrates deeper into the bowel wall, affecting multiple layers of tissue. It also appears in patches skip lesions that leave healthy tissue interspersed with diseased segments. A topical medication designed to coat a continuous surface struggles to reach these isolated, deep-seated areas of inflammation.

Mesalamine Crohn’s formulations attempt to overcome this through various delivery mechanisms. Some use pH-dependent release coatings that dissolve at specific points along the digestive tract. Others rely on time-release technology. But the small bowel presents unique absorption challenges. With a surface area roughly the size of a tennis court and rapid transit times, getting adequate medication concentration at the disease site proves incredibly difficult.

Studies consistently show that anti-inflammatory bowel treatment with 5-ASA compounds achieves therapeutic concentrations primarily in the colon. Patients with disease limited to the colon colonic Crohn’s occasionally respond better than those with ileal or extensive small bowel involvement. But even in colonic disease, penetration into deeper tissue layers remains inadequate for true remission.

Disease Type	5-ASA Efficacy	Remission Rate	Limiting Factor
Ulcerative Colitis	Moderate to Good	40-60%	Continuous inflammation allows topical delivery
Crohn’s Disease (General)	Poor	15-30%	Patchy lesions, transmural inflammation
Colonic Crohn’s Only	Mild to Moderate	30-45%	Better colonic concentration, still superficial

For patients frustrated by medication failure, understanding the mechanism clarifies that the problem isn’t personal it’s pharmaceutical. The drug design itself limits effectiveness in Crohn’s disease. If you’re exploring alternatives, common questions about Crohn’s treatment often reveal options that address inflammation through different pathways.

What 2026 Prescription Data Reveals About Physician Confidence

The prescribing habits of gastroenterologists tell a stark story about clinical reality. Data from Frontiersin shows that among 615 surveyed IBD physicians, confidence in aminosalicylates for Crohn’s management has dropped precipitously. This isn’t pharmaceutical pessimism it’s evidence-based practice evolution.

Sulfasalazine IBD prescriptions have declined as newer immunosuppressive therapies demonstrate superior outcomes. Regional variations persist some European countries maintain higher aminosalicylate prescription rates, while American gastroenterologists have largely abandoned them as primary Crohn’s therapy. The shift reflects accumulated clinical experience rather than marketing influence.

Consider what physicians actually see: patients on mesalamine who maintain symptom profiles nearly identical to untreated disease. Multiple bathroom trips daily. Bleeding that never fully resolves. Inflammation markers that plateau rather than normalize. The gap between prescription and outcome becomes impossible to ignore.

Immunosuppressant preferences have solidified across most practice settings. Thiopurines, methotrexate, and biologic therapies now occupy first-line positions in treatment algorithms for moderate to severe disease. Even for mild Crohn’s, the follow-up data increasingly shows that aminosalicylates delay rather than enable appropriate treatment.

How Traditional Chinese Medicine Targets Inflammation Differently

While Crohn’s medication alternatives continue expanding, traditional Chinese medicine offers a fundamentally different approach to inflammatory bowel disease. Rather than coating the intestinal surface, carefully formulated herbal combinations work systemically addressing inflammation through multiple pathways simultaneously.

Natural IBD remedies derived from Chinese medicine typically combine several herbs, each contributing distinct anti-inflammatory mechanisms. This multi-target strategy contrasts sharply with 5-ASA’s single-pathway approach. Where aminosalicylates primarily inhibit cyclooxygenase and reduce prostaglandin synthesis, herbal formulations may simultaneously modulate immune cell activity, strengthen mucosal barriers, improve blood flow to damaged tissue, and regulate inflammatory cytokine production.

The complexity matters. Chronic intestinal inflammation involves cascading immune responses suppressing one pathway often leads to compensatory activation of others. Single-mechanism drugs face an uphill battle against this biological reality.

• Multi-pathway action: Herbal formulas address inflammation through complementary mechanisms rather than single-target inhibition
• Systemic absorption: Active compounds enter bloodstream, reaching deeper tissue layers that topical medications cannot penetrate
• Mucosal healing: Certain herbs promote epithelial cell regeneration and barrier function restoration
• Immune modulation: Rather than suppressing immunity, formulas help re-regulate dysregulated immune responses
• Reduced resistance: Multi-component formulations don’t face the same tolerance buildup as single-mechanism drugs

For patients interested in how these mechanisms translate to clinical outcomes, the four-herb formula for colonic inflammation demonstrates specific compound interactions that address Crohn’s pathology comprehensively.

The Four-Herb Approach: Why Complexity Beats Simplicity in Crohn’s

The Kronlitis formulation exemplifies how herbal complexity addresses Crohn’s disease more effectively than single-agent therapy. Four carefully selected herbs work synergistically each amplifying the others’ effects while contributing unique therapeutic properties. This isn’t random combination; it’s precision formulation based on traditional Chinese medicine principles validated by modern clinical outcomes.

Customer feedback consistently highlights what clinical trials struggle to capture: life resumption. People who lived bathroom-bound existences report returning to work, eating previously forbidden foods, and traveling without constant location-mapping of restrooms. The intensity and speed of remission distinguish multi-herb approaches from the gradual, partial responses typical of conventional therapy.

Inflammatory bowel disease therapy succeeds when it addresses root causes rather than managing symptoms. The four-herb combination targets inflammation at multiple checkpoints while supporting overall digestive function. Patients report not just reduced bleeding and urgency, but genuine restoration of normal eating patterns and daily activities.

Price point matters too. At €56 for a 90-capsule supply (current pricing), the monthly cost undercuts most pharmaceutical alternatives while delivering outcomes that many prescription medications fail to achieve. The economics align with the clinical reality effective treatment costs less when it actually works.

Reading documented patient remission stories provides concrete examples of how multi-herb therapy translates to daily life improvement for people who previously struggled with treatment-resistant disease.

When Aminosalicylates Make Sense (And When They Don’t)

Despite their limitations, aminosalicylates still occupy a legitimate niche in IBD treatment just a narrower one than previously believed. Understanding when these medications might work helps patients and physicians make informed decisions rather than following outdated protocols.

Colonic Crohn’s treatment with 5-ASA occasionally succeeds when disease remains superficial and limited to the colon. Patients with mild inflammation, no small bowel involvement, and good response to previous medication trials may benefit from continuing aminosalicylate therapy. The key is honest assessment: if symptoms persist unchanged after adequate trial periods, pushing forward with the same approach rarely yields different results.

Disease Location	Severity	5-ASA Appropriateness	Expected Outcome
Colon only	Mild	May consider	Partial response possible
Colon only	Moderate	Usually insufficient	Escalation likely needed
Small bowel involved	Any	Not recommended	Poor efficacy expected
Multiple segments	Any	Inappropriate	Alternative therapy required

The patients who benefit most from staying on aminosalicylates typically have mild disease, excellent response to initial treatment, and no progression over years of monitoring. That profile describes a small subset of the Crohn’s population. For everyone else, continued prescription represents treatment inertia rather than evidence-based care.

Finding targeted solutions for colonic Crohn’s means matching therapy intensity to disease severity and acknowledging when current treatment falls short.

Cost-Benefit Analysis: Aminosalicylates vs Natural Alternatives

Treatment cost extends far beyond prescription price tags. Calculating true cost requires factoring in effectiveness, time to remission, quality of life during treatment, and downstream expenses from inadequate disease control.

Aminosalicylates often appear inexpensive on paper generic mesalamine formulations can cost €30-80 monthly depending on brand and dosage. But that calculation ignores the months or years patients spend on ineffective therapy while inflammation continues damaging intestinal tissue. The cumulative cost of partial treatment adds up quickly.

Affordable natural Crohn’s treatment options[/LINK] like the Kronlitis formulation offer different economics entirely. At €56 monthly, patients receive a multi-pathway therapeutic approach that addresses inflammation comprehensively. The relevant metric isn’t monthly cost it’s cost-per-remission.

Consider the comparison: if aminosalicylates achieve remission in 25% of patients at €50 monthly, while a natural alternative achieves remission in 65% at €56 monthly, the effective cost per successful outcome favors the alternative dramatically. You’re paying for results, not just prescriptions.

Additional cost factors that conventional calculations miss:

• Lost work days from ongoing symptoms
• Emergency room visits during flares
• Secondary medication for side effect management
• Mental health impacts of chronic inadequate treatment

Exploring affordable natural Crohn’s treatment options provides concrete pricing and outcome data for patients weighing their therapeutic choices.

Key Takeaways: Making Informed Decisions About Crohn’s Treatment

The landscape of Crohn’s treatment continues evolving, and staying informed empowers better outcomes. Evidence from 2026 makes several points clear for patients navigating their therapeutic options.

• Aminosalicylates work for ulcerative colitis but fail most Crohn’s patients due to delivery mechanism limitations
• Small bowel disease particularly resists topical 5-ASA therapy absorption and concentration issues prevent adequate dosing
• Physician prescribing patterns show declining confidence in aminosalicylates for Crohn’s across most practice settings
• Multi-pathway approaches address inflammation more comprehensively than single-mechanism drugs
• Herbal formulations combining multiple active compounds can achieve faster, deeper remission through synergistic mechanisms
• Cost-effectiveness calculations should focus on cost-per-remission, not monthly prescription price

Treatment decisions shouldn’t default to tradition. Understanding why how Kronlitis developed effective natural solutions succeeded where conventional approaches often struggle helps patients advocate for care that actually works.

Frequently Asked Questions About Aminosalicylates and Crohn’s Disease

Are aminosalicylates effective for Crohn’s disease remission?

No, not for most patients. Clinical data shows remission rates below 30% for Crohn’s patients on 5-ASA therapy, compared to 40-60% in ulcerative colitis. The patchy, transmural nature of Crohn’s inflammation prevents adequate drug delivery to diseased tissue. Patients with colonic-only disease may see partial benefit, but small bowel involvement typically predicts poor response.

What side effects should I expect from mesalamine?

Generally mild but not negligible. Common effects include nausea, headache, and abdominal discomfort in 10-15% of patients. Rare but serious reactions include kidney inflammation and pancreatitis. For more Crohn’s treatment questions answered, understanding the risk-benefit ratio matters when efficacy itself remains questionable.

Can I combine aminosalicylates with natural treatments?

Yes, typically safely. Natural anti-inflammatory formulations generally don’t interact adversely with 5-ASA medications. However, the better question is whether continuing ineffective therapy makes sense when alternatives demonstrate superior outcomes. Discuss transition strategies rather than mere addition with your healthcare provider.

How long should I try aminosalicylates before switching?

Eight to twelve weeks maximum. If meaningful symptom improvement hasn’t occurred by three months, extending treatment rarely changes outcomes. Disease progression during ineffective therapy risks complications that more aggressive treatment might have prevented. Don’t wait for miracles that the mechanism itself cannot deliver.

Why do doctors still prescribe aminosalicylates if they don’t work well?

Habit, liability concerns, and treatment hierarchies. Many physicians follow step-therapy protocols that mandate trying milder medications first. Insurance requirements often force this progression. Additionally, aminosalicylates carry lower side effect profiles than immunosuppressants, making them a “safe” first step despite limited efficacy.

What’s the success rate of herbal alternatives compared to mesalamine?

Significantly higher in customer outcome data. While direct comparative trials remain limited, multi-herb formulations report remission rates exceeding 60% in customer feedback, compared to aminosalicylates’ sub-30% performance. The multi-pathway approach addresses inflammation more completely than single-mechanism topical therapy. For more Crohn’s treatment questions answered, patient-reported outcomes provide valuable real-world evidence.

@keyframes hoox-lf-in-hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-c90e6a30-014c-4cbb-9065-1a9c27-bottom .hoox-disabled-text a:hover {
text-decoration: none;
}

See What This Could Look Like For You

Takes 30 seconds

Yes, I’m Interested

🎉

Thanks! We’ll be in touch.

Something went wrong. Please try again.